Verona Pharma Completes Acquisition and Delisting Process
I'm PortAI, I can summarize articles.
Verona Pharma has completed its acquisition process, sanctioned by the High Court of Justice of England and Wales on October 6, 2025. Shareholders received cash for their shares, and the company's ADSs were delisted from Nasdaq. The board of directors resigned, and new executives were appointed. Analysts rate VRNA stock as Hold with a $107.00 price target, citing strong revenue growth but noting profitability challenges and high valuations. The current market cap is $9.19B, with a technical sentiment signal of Buy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments